After weeks of uncertainty: Lonza creates 180 new jobs in Switzerland

class=”sc-29f61514-0 icZBHN”>

Lonza expands and expands cooperation with an existing customer. As part of the agreement, the pharmaceutical supplier will install two new systems for the production of antibody-drug conjugates (ADCs) at its main Valais facility in Visp for the unnamed customer.

The two 1,500-square-foot facilities will quadruple its bioconjugate capacity, Lonza said Thursday. The new suites are expected to be operational in 2026 and will create approximately 180 jobs when completed.

Moderna does not use Swiss services

ADCs are complex bioconjugates and are typically used in the selective treatment of cancer cells, according to the notice. Lonza now manufactures most commercially available ADCs.

Lonza recently hit the headlines because the US company Moderna will produce the corona vaccine at its own facilities in the future and will dispense with Switzerland’s services. (pbe/SDA)

more on the subject

Moderna disappointed Lonza

Visp still remains strong

Moderna exit in Lonza

“This is not good news”

Blow to Lonza in Valais

Moderna stopped production of Covid vaccine in Visp

Source :Blick

Tim

I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.